Cochrane · systematic review · CD011260
Sequential inactivated (IPV) and live oral (OPV) poliovirus vaccines for preventing poliomyelitis
Ciapponi, A, Bardach, A, Rey Ares, L, et al. · Cochrane Database of Systematic Reviews · 2019 · Cochrane Library
Developmental, Psychosocial and Learning ProblemsAMSTAR 2: not assessed
SoF tableOnly the outcomes this review put in its Summary of Findings table are listed (the Cochrane Handbook caps them at about seven per comparison). Its other analyses are not shown here.
Questions
21
current version
GRADE rated
13
No studies
0
Included studies
NR
No studies 0 · 0%Ungraded 8 · 38.1%Very low 3 · 14.3%Low 6 · 28.6%Moderate 4 · 19%High 0 · 0%
Ungraded means an effect was reported without a GRADE rating; it is not a gap. No studies means the review found nothing to answer the question. The six categories are a display order, not a score.
Questions and results
IPV‐OPV compared to OPV for preventing poliomyelitis
Population: infants
| Outcome | Effect | Evidence | Status / GRADE |
|---|---|---|---|
Paralytic wild polio cases (Change in slope at 3 years) IPV‐OPV vs OPV | no estimate extracted | 1 participants | Very low Downgraded: risk of bias, imprecision, inconsistency |
Vaccine‐associated paralytic polio (VAPP) cases (Range of IPV‐OPV vs OPV | no estimate extracted | 1 participants | Low Downgraded: risk of bias, imprecision, inconsistency |
Persons with protective humoral response (Range of IPV‐OPV vs OPV | RR 1 [0.99, 1.01] | 12 studies · 3189 participants | Moderate Downgraded: risk of bias, imprecision, inconsistency |
Neutralising antibodies with 2 IPV doses Geometric mean titres (GMT) (Range of IPV‐OPV vs OPV | no estimate extracted | 3 studies · 795 participants | Low Downgraded: risk of bias, imprecision, inconsistency |
Persons with polio faecal excretion after OPV challenge (Range of IPV‐OPV vs OPV | RR 2.24 [0.7, 7.12] | 2 studies · 916 participants | Low Downgraded: risk of bias, imprecision, inconsistency |
Vaccination coverage ( IPV‐OPV vs OPV | RR 1.01 [0.96, 1.06] | 1 participants | Low Downgraded: risk of bias, imprecision, inconsistency |
Serious adverse events (classified by MedDRA) (Range of IPV‐OPV vs OPV | RR 0.88 [0.46, 1.7] | 4 studies · 1948 participants | Low Downgraded: risk of bias, imprecision, inconsistency |
IPV‐OPV compared to IPV for preventing poliomyelitis
Population: infants
| Outcome | Effect | Evidence | Status / GRADE |
|---|---|---|---|
Paralytic wild polio cases at 4 years (Change level from IPV‐OPV to IPV) IPV‐OPV vs IPV | no estimate extracted | 1 participants | Very low Downgraded: risk of bias, imprecision, inconsistency |
Vaccine‐associated paralytic polio cases IPV‐OPV vs IPV | no estimate extracted | 0 studies · 0 participants | Ungraded |
Persons with protective humoral response (Range of IPV‐OPV vs IPV | RR 1 [0.99, 1.01] | 10 studies · 2858 participants | Moderate Downgraded: risk of bias, imprecision, inconsistency |
Neutralising antibodies with 2 IPV doses Geometric mean titres ( IPV‐OPV vs IPV | no estimate extracted | 2 studies · 363 participants | Moderate Downgraded: risk of bias, imprecision, inconsistency |
Persons with faecal polio excretion after OPV challenge (Range of IPV‐OPV vs IPV | RR 0.52 [0.14, 1.97] | 2 studies · 822 participants | Very low Downgraded: risk of bias, imprecision, inconsistency |
Vaccination coverage IPV‐OPV vs IPV | no estimate extracted | 0 studies · 0 participants | Ungraded |
Serious adverse events (≥ 1 symptom related to study drug or not) (Range of IPV‐OPV vs IPV | RR 0.92 [0.6, 1.43] | 2 studies · 1063 participants | Low Downgraded: risk of bias, imprecision, inconsistency |
IPV(3)‐OPV compared to IPV(2)‐OPV for preventing poliomyelitis
Population: preventing poliomyelitis
| Outcome | Effect | Evidence | Status / GRADE |
|---|---|---|---|
Paralytic polio IPV(3)‐OPV vs IPV(2)‐OPV | no estimate extracted | 0 studies · 0 participants | Ungraded |
VAPP cases IPV(3)‐OPV vs IPV(2)‐OPV | no estimate extracted | 0 studies · 0 participants | Ungraded |
Persons with protective humoral response ( IPV(3)‐OPV vs IPV(2)‐OPV | RR 0.98 [0.93, 1.03] | 1 study · 137 participants | Moderate Downgraded: imprecision |
Neutralising antibodies IPV(3)‐OPV vs IPV(2)‐OPV | no estimate extracted | 0 studies · 0 participants | Ungraded |
Persons with faecal excretion after OPV challenge IPV(3)‐OPV vs IPV(2)‐OPV | no estimate extracted | 0 studies · 0 participants | Ungraded |
Vaccination coverage IPV(3)‐OPV vs IPV(2)‐OPV | no estimate extracted | 0 studies · 0 participants | Ungraded |
Serious adverse events IPV(3)‐OPV vs IPV(2)‐OPV | no estimate extracted | 0 studies · 0 participants | Ungraded |